BridgeMD
Upadacitinib in adult patients with erosive mucosal Lichen Planus and Lichen Planopilaris.
EU CTIS ID: 2025-522870-35-00
What this study is testing
To assess the clinical efficacy of upadacitinib 30 mg daily (QD) in subjects with erosive MLP and in subjects with LPP when compared to placebo after 16 weeks of treatment
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Written informed consent must be obtained before any assessment is performed
- Female and male patients ≥ 18 years and < 65 years old at Baseline Visit
- Subjects must have biopsy-confirmed forms of mucosal lichen planus (MLP) or active lichen planopilaris (LPP) eligible for systemic therapy based on the following criteria: · Rated IGA of ≥ 3 (moderate or severe) AND · Inadequate response to topical corticosteroids of high - ultrahigh potency in the opinion of the investigator
- A negative serum pregnancy test for all female subjects considered to be of childbearing potential at the Screening Visit and a negative urine pregnancy test at baseline prior to the first dose of study drug.
You likely can't join if
- Clinical history suspicious for lichenoid drug eruption
- Clinical picture or history suspicious of paraneoplastic mucosal lichen planus
- Mucosal lichen planus of the oral cavity or gastrointestinal involvement requiring the patient to use parenteral nutrition or feeding tube
- Clinical picture of burnt-out cicatricial alopecia (alopecia of Brocq)
- Patients diagnosed with frontal fibrosing alopecia (FFA) without active patches of LPP
- Hepatitis C antibody positive at screening unless viral load is 0
See the full eligibility criteria
- Written informed consent must be obtained before any assessment is performed
- Female and male patients ≥ 18 years and < 65 years old at Baseline Visit
- Subjects must have biopsy-confirmed forms of mucosal lichen planus (MLP) or active lichen planopilaris (LPP) eligible for systemic therapy based on the following criteria: · Rated IGA of ≥ 3 (moderate or severe) AND · Inadequate response to topical corticosteroids of high - ultrahigh potency in the opinion of the investigator
- A negative serum pregnancy test for all female subjects considered to be of childbearing potential at the Screening Visit and a negative urine pregnancy test at baseline prior to the first dose of study drug.
- Clinical history suspicious for lichenoid drug eruption
- Clinical picture or history suspicious of paraneoplastic mucosal lichen planus
- Mucosal lichen planus of the oral cavity or gastrointestinal involvement requiring the patient to use parenteral nutrition or feeding tube
- Clinical picture of burnt-out cicatricial alopecia (alopecia of Brocq)
- Patients diagnosed with frontal fibrosing alopecia (FFA) without active patches of LPP
- Hepatitis C antibody positive at screening unless viral load is 0
- Subjects with active TB or latent TB without history of appropriate prophylaxis
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.